Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
5.40
-0.24 (-4.26%)
Feb 21, 2025, 4:00 PM EST - Market closed
Ensysce Biosciences Employees
Ensysce Biosciences had 7 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$631,629
Profits / Employee
-$1,132,443
Market Cap
7.05M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7 | 0 | - |
| Dec 31, 2022 | 7 | 1 | 16.67% |
| Dec 31, 2021 | 6 | 3 | 100.00% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
ENSC News
- 18 days ago - Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment - Accesswire
- 4 weeks ago - Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR - Accesswire
- 6 weeks ago - Ensysce Biosciences Issues Annual Shareholder Letter - Accesswire
- 2 months ago - Ensysce Biosciences Regains Full Compliance with Nasdaq - Accesswire
- 2 months ago - Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product - Accesswire
- 2 months ago - Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR - Accesswire
- 2 months ago - Ensysce Biosciences Announces 1-for-15 Reverse Stock Split - Accesswire
- 3 months ago - Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial - Accesswire